Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 2 | History Defined

3 Biotech Stocks to Buy in 2023 That Could Help Set You up for Life

The biotech industry is well-positioned to witness significant growth on the backs of soaring demands and government spending. Moreover, given the sector’s defensive nature, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and United Therapeutics Corp. (UTHR) might be solid buys in 2023 that could help you set for life.…

The 3 Hottest Biotech Stocks to Own in 2023 and 1 to Avoid

The 3 Hottest Biotech Stocks to Own in 2023 and 1 to Avoid

Biotech companies are on track to stay resilient amid a potential economic slowdown due to their inelastic demand and continued breakthroughs. Therefore, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), United Therapeutics (UTHR), and Jazz Pharmaceuticals (JAZZ). On the other hand, Bionano Genomics (BNGO)…

5 Biotech Stocks That Could Make You Rich in 10 Years

5 Biotech Stocks That Could Make You Rich in 10 Years

The biotech industry is rapidly growing amid rising private and government investments and technological advancements. Given the solid prospects of the industry, fundamentally strong biotech stocks Amgen (AMGN), Vertex (VRTX), United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be ideal long-term investments for steady returns. Keep reading.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

2 Biotech Stocks to Buy and 1 to Avoid Like the Plague

The biotech industry is expected to witness solid growth driven by growing government initiatives and increasing demand across several sectors. While we think fundamentally sound biotech stocks Gilead Sciences (GILD) and United Therapeutics (UTHR) could be solid buys this year, Bionano Genomics (BNGO) could be best avoided considering its fundamental…

3 Biotech Stocks to Buy Before December and 1 to Sell

The biotech industry is increasingly gaining prominence due to the growing prevalence of chronic disease and advancements in drug discovery and development. Given the industry’s solid growth prospects, it could be wise to buy quality biotech stocks, Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and United Therapeutics (UTHR). However, we think…

5 Biotech Stocks to Buy and Hold for the Next Decade

The biotech industry seems poised to witness solid growth over the next decade with intensive innovation, breakthrough developments, and growing investments in the sector. So, given analysts’ promising growth outlook for the industry, it could be wise for investors to buy and hold fundamentally solid biotech stocks Vertex Pharmaceuticals (VRTX),…

4 "Strong Buy" Biotech Stocks to Add to Your Watchlist

As the Biotech industry’s role in finding cures for chronic diseases and critical conditions is expected to keep attracting investors’ attention, it could be wise to scoop up shares of the fundamentally-strong biotech companies Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR), Amgen (AMGN), and Sino Biopharmaceutical (SBHMY) because of their solid…

inkl

Read news from The Economist, FT, and more,
with one subscription

Will Investors Notice Exciting Sign On United Therapeutics's Chart?

Will Investors Notice Exciting Sign On United Therapeutics's Chart?

If history is any guide, there may be good fortune ahead for shares of United Therapeutics (NASDAQ:UTHR). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Short Volatility Alert: United Therapeutics Corporation

Short Volatility Alert: United Therapeutics Corporation

On Wednesday, shares of United Therapeutics Corporation (NASDAQ: UTHR) experienced volatile short activity. After the activity, the stock price went up 4.31% to $228.39. The overall sentiment for UTHR has been Bullish.

Expert Ratings for United Therapeutics

Expert Ratings for United Therapeutics

Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings:

5 Undervalued Stocks to Scoop Up in May

5 Undervalued Stocks to Scoop Up in May

The market selloff caused by the difficult macroeconomic and geopolitical issues has led many quality stocks to now trade below their intrinsic values. Agilent Technologies (A), United Therapeutics (UTHR), Nissan Motor (NSANY), Bausch Health (BHC), and Encore Wire (WIRE) are examples. These names are currently trading at discounts to their…

Recap: United Therapeutics Q1 Earnings

Recap: United Therapeutics Q1 Earnings

United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Earnings Outlook For United Therapeutics

Earnings Outlook For United Therapeutics

United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that United Therapeutics will report an earnings per share (EPS) of $3.34.

Take Advantage of These 5 'Strong Buy' Stocks Down More Than 10% YTD

Take Advantage of These 5 'Strong Buy' Stocks Down More Than 10% YTD

Amid deepening supply disruptions and record-high inflation, expected aggressive federal interest rate increases, and the resurgence of COVID-19 cases have been driving market volatility. However, we think quality stocks Agilent (A), Olympus (OCPNY), F5 (FFIV), Jones Lang LaSalle (JLL), and United Therapeutics (UTHR), which are down more than 10% in…

Get all your
news in one place.

100's of premium titles.
One news app.

First Human With Pig Heart Transplant Dies

A 57-year-old man with terminal heart disease who became the first person to receive a genetically modified pig's heart has died, the University of Maryland Medical Center (UMMC) said. The hospital said that David Bennett's condition started deteriorating several days ago, adding that Bennett was given "compassionate palliative care." In October,…

United Therapeutics Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, United Therapeutics (NASDAQ:UTHR) posted Q4 earnings of $112.20 million, an increase from Q3 of 31.04%. Sales dropped to $415.20 million, a 6.63% decrease between quarters.

FDA Pushes United Therapeutics-MannKind Tyvaso DPI's Decision Date; United Therapeutics' Q4 Misses Consensus

United Therapeutics Corp (NASDAQ: UTHR) and its partner MannKind Corp (NASDAQ: MNKD) have received an FDA information request letter for

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Gilead Sciences Inc

Gilead Sciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

398,597 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play